70 completed, 17 unknown, 7 recruiting, 6 active not recruiting. 113 Phase 1, 46 Phase 2.
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage ASP2767, Sham ASP2767, Prophylactic Regimen A - Glaucoma | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 156 | 2026-10-07 | 2026-10-22 |
| Topical Insulin for Glaucoma (TING2) EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month) - Open Angle Glaucoma, Primary Open Angle Glaucoma | Phase 1 / Phase 2 | Enrolling by invitation | Stanford University | 90 | 2026-09-10 | 2026-10-13 |
| REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension REGN22530 - Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 271 | 2026-09-08 | 2026-09-28 |
| Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension BIM-DRS Low Dose, BIM-DRS High Dose, SpyGlass IOL with silicone pads (no drug) - Glaucoma, Ocular Hypertension | Phase 1 | Not yet recruiting | SpyGlass Pharma, Inc. | 24 | 2026-07-31 | 2026-06-11 |
| Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions) ER-100 epigenetic therapy - Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy) | Phase 1 | Recruiting | Life Biosciences Inc. | 18 | 2026-03-02 | 2026-05-19 |
| GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma GVB-2001-high dose, GVB-2001-low dose - Primary Open-Angle Glaucoma (POAG) | Phase 1 / Phase 2 | Recruiting | IVIEW Therapeutics Inc. | 6 | 2025-11-19 | 2026-05-04 |
| Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery TimoD implant, Injector system, Timolol eye drops 0.5% - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Recruiting | EyeD Pharma | 42 | 2025-06-12 | 2026-07-30 |
| Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension PA5436 Ocular Implant, 115mcg - Open Angle Glaucoma (OAG), Ocular Hypertension (OH) | Phase 1 | Active not recruiting | PolyActiva Pty Ltd | 12 | 2025-06-10 | 2026-07-07 |
| Pilot Study on a New Self Adjustable Glaucoma Drainage Device eyeValve - Glaucoma | Phase 1 | Active not recruiting | Rheon Medical SA | 10 | 2025-06-01 | 2026-03-18 |
| Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting Lignocaine-loaded maltose microneedle array patch, EMLA 5% patch - Glaucoma, Cataract | Phase 1 / Phase 2 | Recruiting | Universiti Kebangsaan Malaysia Medical Centre | 154 | 2025-02-17 | 2025-07-18 |
| Open-Label Study of Safety of H1337 in Healthy Volunteers H-1337 1.0% - Glaucoma Open-Angle Primary, Ocular Hypertension | Phase 1 | Completed | D. Western Therapeutics Institute, Inc. | 17 | 2024-09-16 | 2025-02-11 |
| Clinical Study of FB1001 in Patients FB1001 - Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy | Phase 1 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-08-15 | 2024-07-17 |
| Effect of Latanoprost on Optic Nerve Perfusion Latanoprost (0.005%) - Treatment Outcome | Phase 1 | Completed | Zagazig University | 46 | 2024-06-24 | 2024-10-08 |
| Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension Latanoprost eluting contact lens, Topical Latanoprost - Glaucoma, Ocular Hypertension | Phase 1 | Terminated | Massachusetts Eye and Ear Infirmary | 1 | 2024-04-03 | 2025-10-15 |
| A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes Bimatoprost Ophthalmic Solution, 0.01%, LUMIGAN® (bimatoprost ophthalmic solution) 0.01% - Open-angle Glaucoma, Ocular Hypertension | Phase 1 | Unknown | Amneal Pharmaceuticals, LLC | 240 | 2024-04-01 | 2024-08-06 |
| Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 1 / Phase 2 | Active not recruiting | SpyGlass Pharma, Inc. | 201 | 2023-10-13 | 2025-08-22 |
| A Study of PER-001 in Participants With Open-Angle Glaucoma PER-001 Intravitreal Implant - Low Dose, PER-001 Intravitreal Implant - High Dose, PER-001 Intravitreal Implant - Sham - Open-angle Glaucoma | Phase 1 / Phase 2 | Completed | Perfuse Therapeutics, Inc. | 33 | 2023-05-25 | 2026-06-05 |
| Safety of Topical Insulin Drops for Open-angle Glaucoma Topical insulin (4 units), Topical insulin (20 units), Artificial tears - Glaucoma | Phase 1 | Unknown | Centre hospitalier de l'Université de Montréal (CHUM) | 18 | 2023-03-27 | 2024-08-21 |
| Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma TimoD implant, Injector system - Primary Open-angle Glaucoma | Phase 1 | Terminated | EyeD Pharma | 1 | 2023-03-01 | 2025-07-16 |
| A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension TO-O-1001, Placebo - Open Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Unknown | Theratocular Biotek Co. | 50 | 2022-08-04 | 2023-10-19 |
Showing 20 of 113. Sign in to see all of them.
Glaucoma, Open-Angle (57) · Ocular Hypertension (56) · Eye Diseases (5) · Cataract (4) · Optic Nerve Diseases (4) · Glaucoma, Neovascular (3) · Hydrophthalmos (3) · Retinal Degeneration (2) · Carotid Stenosis (1) · Diabetic Retinopathy (1) · Disease (1) · Exfoliation Syndrome (1) · Glaucoma, Angle-Closure (1) · Lens Diseases (1)
Eye Diseases (108) · Ocular Hypertension (57) · Nervous System Diseases (6) · Cranial Nerve Diseases (5) · Retinal Diseases (5) · Cardiovascular Diseases (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Eye Abnormalities (3) · Glaucoma, Open-Angle (3) · Infant, Newborn, Diseases (3) · Lens Diseases (3) · Uveal Diseases (3) · Vascular Diseases (3)
Latanoprost (10) · Bimatoprost (5) · Timolol (5) · Ranibizumab (4) · Insulin (3) · Mitomycin (3) · Ophthalmic Solutions (3) · Drugs, Investigational (2) · Trabeculectomy (2) · dorzolamide (2) · Bosentan (1) · Brimonidine Tartrate (1) · Brimonidine Tartrate, Timolol Maleate Drug Combination (1) · Culture Techniques (1) · DMAC2L protein, human (1)
PolyActiva Pty Ltd (4) · Allergan (3) · Santen Inc. (3) · Shahid Beheshti University of Medical Sciences (3) · Stanford University (3) · Alcon Research (2) · Annexon, Inc. (2) · Bausch & Lomb Incorporated (2) · Chong Kun Dang Pharmaceutical (2) · EyeD Pharma (2) · ForSight Vision5, Inc. (2) · Hoffmann-La Roche (2) · Laboratorios Sophia S.A de C.V. (2) · Massachusetts Eye and Ear Infirmary (2) · Merck Sharp & Dohme LLC (2)
United States (55) · Australia (6) · Germany (5) · South Korea (4) · Spain (4) · United Kingdom (4) · Austria (3) · Canada (3) · China (3) · Iran (3) · Mexico (3) · New Zealand (3) · Singapore (3) · Azerbaijan (2) · Brazil (2)
Jeffrey L Goldberg, MD, PhD (3) · David Wirta, MD (2) · Eric Humphriss (2) · Alina K Drakon, MD (1) · Anne Rubin (1) · Auli Ropo (1) · Barbara Wirostko, MD (1) · Barrett Katz, MD (1) · Belen Sadaba, MD, PhD (1)
PMID 34707360, PMID 19290537, PMID 20570237, PMID 26453641, PMID 29802818, PMID 33469852, PMID 34780798, PMID 35643967, PMID 35696700, PMID 35943114, PMID 36055467, PMID 36912740, PMID 42213132
2014 (2), 2008 (1), R43EY023122 (1)